**S5 Table.** Post-hoc analysis with an additional criterion for drug use in the Daegu/Gyeongsangbuk-do population, requiring a prescription of ≥30 days within 6 months before the coronavirus disease testing

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug** | **Controls(N=7,553)** | **Cases(N=1,335)** | **Crude** | **Adjusted** |
| **OR** **(95% CI)** | **P** | **OR** **(95% CI)** | **P** |
| **Drugs with potential therapeutic effects** |
| Hydroxychloroquine | 7 (0.09) | 1 (0.07) | 0.81 (0.10–6.57) | 0.842 | 1.04 (0.11–10.19) | 0.973 |
| Camostat | 3 (0.04) | 0 (0.00) |  | >0.999 |  | 0.978 |
| Statins | 477 (6.32) | 96 (7.19) | 1.15 (0.92–1.44) | 0.230 | 1.30 (0.96–1.75) | 0.094 |
| Mycophenolate | 4 (0.05) | 2 (0.15) | 2.83 (0.52–15.48) | 0.224 | 3.78 (0.61–23.52) | 0.154 |
| Amiodarone | 9 (0.12) | 0 (0.00) |  | 0.959 |  |  |
| **Drugs with concerns regarding increased risk** |
| Angiotensin receptor blockers | 419 (5.55) | 87 (6.52) | 1.19 (0.94–1.51) | 0.159 | 1.06 (0.78–1.45) | 0.697 |
| Angiotensin-converting enzyme inhibitors | 35 (0.46) | 8 (0.60) | 1.30 (0.60–2.80) | 0.510 | 1.74 (0.75–4.04) | 0.195 |
| Metformin | 174 (2.30) | 30 (2.25) | 0.98 (0.66–1.44) | 0.900 | 0.99 (0.64–1.55) | 0.968 |
| Thiazolidinedione | 31 (0.41) | 9 (0.67) | 1.65 (0.78–3.47) | 0.187 | 1.30 (0.57–3.00) | 0.536 |
| **Drugs with no expected benefits** |
| NSAIDs | 322 (4.26) | 53 (3.97) | 0.93 (0.69–1.25) | 0.623 | 0.81 (0.58–1.14) | 0.223 |
| COX2 inhibitors | 92 (1.22) | 11 (0.82) | 0.67 (0.36–1.26) | 0.219 | 0.55 (0.27–1.12) | 0.100 |
| Aspirin | 6 (0.08) | 0 (0.00) |  | 0.950 |  |  |
| Systemic steroids | 164 (2.17) | 14 (1.05) | 0.48 (0.28–0.83) | 0.008 | 0.43 (0.23–0.78) | 0.006 |
| Proton pump inhibitors | 397 (5.26) | 64 (4.79) | 0.91 (0.69–1.19) | 0.483 | 1.02 (0.73–1.43) | 0.901 |
| N-acetylcysteine | 83 (1.10) | 11 (0.82) | 0.75 (0.40–1.41) | 0.367 | 0.84 (0.42–1.67) | 0.622 |